Short interest in OUST stock price declined last week, suggesting bearish bets are being unwound amid stronger-than-expected shipment data. It remains to be seen how much long-term damage the autism controversy will cause for Kenvue. With the quick and strong backlash from reputable medical groups, the company's Tylenol sales might not be impacted much. This company is expected to post quarterly loss of $0.48 per share in its upcoming report, which represents a year-over-year change of +9.4%. Revenues are expected to be $34 million, up 26% from the year-ago quarter. As of midday, OUST stock price traded at $5.58, with technical charts showing a bullish golden cross forming on the daily moving averages.